Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA.
Rigontec GmbH
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://rigontec.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
AddressAm Klopferspitz 19, 82152PlaneggGermany
Am Klopferspitz 19, 82152
Planegg
Germany
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]